Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)
<p>Abstract</p> <p>Background</p> <p>The use of imatinib mesylate is associated with a progression free survival of 41 months in first line treatment of metastatic or locally advanced gastrointestinal stromal tumors (GIST) and other studies approved that adjuvant imatin...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2407/12/186 |
id |
doaj-676e04fd5e02475eab91968f999dd20f |
---|---|
record_format |
Article |
spelling |
doaj-676e04fd5e02475eab91968f999dd20f2020-11-25T00:18:45ZengBMCBMC Cancer1471-24072012-05-0112118610.1186/1471-2407-12-186Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)Seidel ChristophFenner MartinLänger FlorianBantel HeikeGanser ArnoldGrünwald Viktor<p>Abstract</p> <p>Background</p> <p>The use of imatinib mesylate is associated with a progression free survival of 41 months in first line treatment of metastatic or locally advanced gastrointestinal stromal tumors (GIST) and other studies approved that adjuvant imatinib treatment improves the recurrence-free survival in patients with GIST. Current recommendations include 1 year adjuvant treatment in GIST patients at risk but active studies explore different durations of treatment with an interval of up to 5 years. While the most frequent adverse events (AEs) are blood count alterations, abdominal discomfort and edema, the occurrence of grade 3 or 4 increase of AST or ALT is specified with 2.1% and 2.7% respectively.</p> <p>Case presentation</p> <p>We report a 49-year old male with a gastrointestinal stromal tumor (GIST) of the small bowel who developed liver cirrhosis under adjuvant imatinib treatment.</p> <p>Conclusions</p> <p>Our report supports the notion that imatinib-induced hepatotoxicity may lead to acute liver damage with subsequent cirrhotic remodelling. Patients developing grade 3 or 4 hepatotoxicity during imatinib treatment should therefore be carefully evaluated for chronic liver disease.</p> http://www.biomedcentral.com/1471-2407/12/186GISTImatinibLiver cirrhosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Seidel Christoph Fenner Martin Länger Florian Bantel Heike Ganser Arnold Grünwald Viktor |
spellingShingle |
Seidel Christoph Fenner Martin Länger Florian Bantel Heike Ganser Arnold Grünwald Viktor Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST) BMC Cancer GIST Imatinib Liver cirrhosis |
author_facet |
Seidel Christoph Fenner Martin Länger Florian Bantel Heike Ganser Arnold Grünwald Viktor |
author_sort |
Seidel Christoph |
title |
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST) |
title_short |
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST) |
title_full |
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST) |
title_fullStr |
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST) |
title_full_unstemmed |
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST) |
title_sort |
imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (gist) |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2012-05-01 |
description |
<p>Abstract</p> <p>Background</p> <p>The use of imatinib mesylate is associated with a progression free survival of 41 months in first line treatment of metastatic or locally advanced gastrointestinal stromal tumors (GIST) and other studies approved that adjuvant imatinib treatment improves the recurrence-free survival in patients with GIST. Current recommendations include 1 year adjuvant treatment in GIST patients at risk but active studies explore different durations of treatment with an interval of up to 5 years. While the most frequent adverse events (AEs) are blood count alterations, abdominal discomfort and edema, the occurrence of grade 3 or 4 increase of AST or ALT is specified with 2.1% and 2.7% respectively.</p> <p>Case presentation</p> <p>We report a 49-year old male with a gastrointestinal stromal tumor (GIST) of the small bowel who developed liver cirrhosis under adjuvant imatinib treatment.</p> <p>Conclusions</p> <p>Our report supports the notion that imatinib-induced hepatotoxicity may lead to acute liver damage with subsequent cirrhotic remodelling. Patients developing grade 3 or 4 hepatotoxicity during imatinib treatment should therefore be carefully evaluated for chronic liver disease.</p> |
topic |
GIST Imatinib Liver cirrhosis |
url |
http://www.biomedcentral.com/1471-2407/12/186 |
work_keys_str_mv |
AT seidelchristoph imatinibinducedlivercirrhosisinapatientwithadvancedgastrointestinalstromatumorgist AT fennermartin imatinibinducedlivercirrhosisinapatientwithadvancedgastrointestinalstromatumorgist AT langerflorian imatinibinducedlivercirrhosisinapatientwithadvancedgastrointestinalstromatumorgist AT bantelheike imatinibinducedlivercirrhosisinapatientwithadvancedgastrointestinalstromatumorgist AT ganserarnold imatinibinducedlivercirrhosisinapatientwithadvancedgastrointestinalstromatumorgist AT grunwaldviktor imatinibinducedlivercirrhosisinapatientwithadvancedgastrointestinalstromatumorgist |
_version_ |
1725374660342710272 |